Publications by authors named "Mark Offer"

Claim this Profile
I
Ixazomib, lenalidomide, and dexamethasone is effective and well tolerated in multiply relapsed (≥2nd relapse) refractory myeloma: a multicenter real world UK experience.
Nadjoua Maouche, Bhuvan Kishore, Matthew W Jenner, Kevin Boyd, Zara Bhatti, Mark Offer

Leuk Lymphoma· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Carfilzomib therapy for relapsed myeloma: results of a UK multicentre experience.
Faouzi Djebbari, Huben Hubenov, Pratap Neelakantan, Julia Wolf, Mark Offer

Br J Haematol· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical profile and treatment outcome of older (>75 years) patients with systemic AL amyloidosis.
Sajitha Sachchithanantham, Mark Offer, Christopher Venner, Shameem A Mahmood, Darren Foard

Haematologica· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The serological diagnostic challenges of multiple myeloma.
Yisu Gu, Terrence Hunter, Mark Offer

Br J Hosp Med (Lond)· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis.
Julian D Gillmore, Glenys A Tennent, Winston L Hutchinson, Janet Ruth Gallimore, Helen J Lachmann, Mark Offer

Br J Haematol· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiac amyloidosis, a monoclonal gammopathy and a potentially misleading mutation.
Ashutosh D Wechalekar, Mark Offer, Julian D Gillmore, Philip N Hawkins, Helen J Lachmann

Nat Clin Pract Cardiovasc Med· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease.
Ashutosh D Wechalekar, Helen J Lachmann, Mark Offer, Philip N Hawkins, Julian D Gillmore

Haematologica· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis.
Ashutosh D Wechalekar, Hugh J B Goodman, Helen J Lachmann, Mark Offer, Philip N Hawkins

Blood· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis.
Julian D Gillmore, Hugh J Goodman, Helen J Lachmann, Mark Offer, Ashutosh D Wechalekar

Blood· February 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis